Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986196

Next Previous
X
Search
Drug Profile

BMS 986196

Alternative Names: BMS-986196

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 18 Dec 2023 Bristol-Myers Squibb completes a phase-I clinical trials in Multiple sclerosis in United Kingdom (IV) (NCT05064436)
  • 22 Oct 2023 Bristol-Myers Squibb completes a phase I pharmacokinetics trial (In volunteers) in USA (NCT05981963)
  • 11 Oct 2023 Pharmacokinetics and adverse events data from a phase I trial in Multiple sclerosis presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis, 2023 (Joint ECTRIMS-ACTRIMS 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top